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A study on the levels of calmodulin and DNA in human lung cancer cells
G-X Liu, H-F Sheng and S Wu
Department ofRespiratory Disease, Southwest Hospital, Third Military Medical University, Gaotanyan 630038, Chongqing,
Sichuan Province, People's Republic of China.
Summary In order to study the role of calmodulin (CaM) in the proliferation of lung cancer cells, the CaM
level of the specimens of40 cases ofprimary lung cancers and the DNA content of the specimens of 35 cases of
primary lung cancers were determined with phosphodiesterase assay and flow cytometry respectively. It was
found that the CaM level of lung cancers was significantly higher than that of host lungs, benign lung diseases
and normal lungs (P<0.001) and that it was significantly correlated with the histopathological grading and
TNM staging of the lung cancers. It was also found that the cellular DNA content of lung cancers, like the
CaM level, was also significantly higher than that of benign lung diseases and normal lungs (P<0.001). There
was a significant positive correlation between the cellular DNA content and tissue CaM level in lung cancers
(r =0.885). It is believed that CaM plays an important role in the proliferation of lung cancer cells through the
mechanism of the promotion of an uncontrolled synthesis of DNA in the cells. Consequently, it is inferred that
CaM antagonists may be tried as a chemotherapeutic agent for lung cancer.
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Calmodulin (CaM) is a major intracellular calcium receptor.
Being a central pluripotent regulator of cell functions, it plays
an important role in the growth and proliferation of cells
(Chafouleas et al., 1982; Sasaki and Hidaka, 1982; Means
and Rasmussen, 1988). It was reported that the CaM level
was higher in cancer cells than in normal cells and there was
a positive correlation between the growth rate and CaM level
of cancer cells (Criss and Kakjuchi, 1982; Wei et al., 1982;
Hickie et al., 1983). Until now, there has been no paper
concerning the relationship between CaM level and the
development of lung cancers. In our study the CaM level and
DNA content were determined in samples from human
primary lung cancers in order to study the role that CaM
played in the proliferation of lung cancer cells and the
possibility that CaM antagonists might be useful in the
treatment of lung cancer.
Materials and methods
Forty surgical specimens of human primary lung cancers (18
squamous cell carcinoma, 19 adenocarcinoma and three
small-cell carcinoma), 20 specimens of benign pulmonary
diseases (nine cases of pulmonary tuberculosis, five inflam-
matory pseudotumour, four hamartoma and two chronic
pneumonia), 20 specimens of host lungs taken from the same
lobe containing the lung cancer but situated 2.5 cm away
from the lesion and 20 specimens of normal lungs taken from
patients who had died in traffic accidents were studied. All
the tissue specimens were washed with 0.9% salt solution and
the necrotic part was removed. They were immediately frozen
and stored at -80'C or fixed in 10% neutral formalin and
embedded in paraffin.
When the CaM level was to be measured the tissue
specimen was homogenised in 50 mM Tris-HCl, pH 7.0,
containing 1 mM EGTA using a Brinkman polytron
homogeniser. The homogenate was centrifuged at 100 000 g
for 30 min. The supernatant was rapidly heated to 1000C in a
boiling water bath for 5 min. The denatured protein in the
supernatant was removed by centrifugation at 20 000 g for
30 min. The second supernatant was dialysed against 4.5 mM
calcium chloride solution and used to assay CaM, whose
capacity to stimulate the activity of phosphodiesterase (PDE)
was determined in a two-step procedure as follows:
[3H]cAMP P [3H]5-AMP
snake venom
[3H] -AMP [3H]adenosine + Pi
(A)
(B)
Finally, the CaM level was calculated from the radiation
emitted from [3H]adenosine (Wallace et al., 1983; Liu et al.,
1985).
Flow cytometric analysis of DNA content was performed
as follows.
The paraffin-embedded tissue blocks were sliced into
sections 50 gm in thickness. The sections were deparaffinised
in xylene and rehydrated in a series of progressively
decreasing concentrations of ethanol. The tissue sections
were washed with redistilled water and incubated with 0.5%
pepsin, pH 1.5, at 370C for 30 min. After pepsin digestion,
the disaggregation was completed mechanically. Pepsin
proteolysis was interrupted with the addition of pepstatin.
Undigested tissue fragments were filtrated out with a fine
200-hole nylon mesh. After washing and centrifuging, the
pellets were fixed in 70% ethanol and stored at 40C ready for
assay.
The human cells were routinely adjusted to 105 ml-l in
concentration, stained with ethium bromide and analysed on
a FACS 420 (Becton Dickinson, USA) equipped with a
300 mW argon ion vapour laser lamp, wavelength 488 nm.
DNA was expressed by the DNA index (DI), which was
calculated with the following equation.
DI Mean channel number of the sample cells Go +G1 peak
Mean channel number of lymphocytes Go + G1 peak
All the data were analysed on a microcomputer with the
software SPLM programmed by the Department of Medical
Statistics of the Third Military Medical University. Student's
t-test was used to determine the P-value between two
parameters.
Results
The CaM level was significantly higher in lung cancers than
in the host lungs, benign pulmonary diseases and normal
lungs (P<0.001) (Table I).
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Table 1 CaM level in four kinds of lung tissues (jug mg 1 protein,
mean±s.d.)
Groups n CaM level
Normal lungs 20 0.594±0.145
Host lungs 20 0.601 +0.150a
Benign lung diseases 20 0.726±0.18ib
Lung cancers 40 1.053 +0.206c
ap>0.05 compared with that of the normal. bp<0.05 compared
with that ofthe normal and the host lungs. 'P<0.001 compared with
that ofthe other three groups.
Table II Relationship between tissue CaM level and histopatholo-
gical grading of lung cancers (jg mg' protein, meanis.d.)




The histopathological features of 13 cases were atypical and it was
difficult to give them a grade. They were excluded from this analysis.
ap<0.05 compared with that ofgrade I. bp>0.05 compared with that
ofgrade II.
Table III Relationship between tissue CaM level and TNM staging
of lung cancers (jig mg 1 protein, mean ±s.d.)




ap>0.05. bp<0.05 compared with that of stage I. CP>0.05
compared with that of stage II.
Table IV Relationship between tissue CaM level and pathological
types of lung cancers (jig mg1 protein, mean ±s.d.)
Pathological types n Tissue CaM level
Squamous cell carcinoma 18 1.072 0.240
Adenocarcinoma 19 1.016±0.178a
Small cell carcinoma 3 1.174 +0.11la
ap>0.OS compared with either that of squamous cell carcinoma or
adenocarcinoma.
The CaM level of lung cancer cells was positively
correlated with the histopathological grading and TNM
staging of lung cancers (Table II and III) but no correlation
was observed between the pathological types of lung cancers
and tissue CaM level (Table IV).
The cellular DNA content of the lung cancer cells was
significantly higher than that of benign lung diseases and
normal lungs (P<0.001) (Table V).
A significant positive correlation was observed between
cellular DNA content and tissue CaM level in 27 specimens
of human primary lung cancers (r=0.885).
Discussion
CaM is a versatile intracellular calcium receptor that can
modulate the activities of several enzymes and many
physiological and pathological processes to affect cell
division and proliferation directly or indirectly (Chafouleas
et al., 1982; Sasaki and Hidaka, 1982; Means and
Rasmussen, 1988). Many studies reported that there was an
increase in CaM level in tumour cells or any transformed
cells. Singer et al. (1976) reported that the CaM level of
human breast carcinoma was higher than that of the normal
control. Takemoto and Jilka (1983) found that the CaM level
of leukaemic cells was 5-10 times higher than that of normal
lymphocytes. Wei et al. (1981, 1982) showed that Morris
Table V Cellular DNA content of lung cancers, benign lung
diseases and normal lungs (mean±s.d.)
Groups n DNA index
Normal lungs 10 0.996±0.022
Benign lung diseases 10 1.014±0.042a
Lung cancers 35 1.320±0.220b
The cellular DNA content was not determined in five cases oflung
cancer. ap>0.05 compared with that of normal lungs. bp<0.001
compared with that ofnormal lungs and benign lung diseases.
hepatomas with different growth rates induced by various
means all contained more CaM than normal adult or fetal
liver and that there was a positive correlation between CaM
level and the growth rate of hepatomas. But Moon et al.
(1983) demonstrated a contrary result: that the CaM level of
human renal carcinoma showed no significant difference from
that of the normal control. It was found in our study that the
tissue CaM level of lung cancers was significantly higher than
that of benign lung diseases, host lungs and normal lungs
(P<0.001) and was positively correlated with the histopatho-
logical grading and TNM staging of lung cancers. It is
believed that the increased tissue CaM level may be one of
the factors to promote the proliferation of lung cancer cells.
Experiments on the liver cells of T5, B rats demonstrated
that trifluoperazine, a CaM antagonist, could stop the
initiation and continuation of DNA synthesis and the
inhibition of DNA synthesis by trifluoperazine in the liver
cells was reversed with the administration of purified rat
CaM (Boynton et al., 1980), which implies that CaM plays an
important role in DNA synthesis in the liver cells. The
excessive proliferation of cancer cells results from uncon-
trolled DNA synthesis. It remains unclear whether increase in
CaM level could promote uncontrolled DNA synthesis. It
was found in our study that both cellular DNA content and
tissue CaM level were higher in lung cancers than in benign
pulmonary diseases and normal lungs and there was a
significantly positive correlation between cellular DNA
content and tissue CaM level in lung cancers (r =0.885).
Therefore, it is considered that the increased CaM level is
able to promote uncontrolled DNA synthesis, and this may
be one of the main aspects of the role of CaM in lung cancer
cell proliferation.
Recent evidence confirmed that CaM antagonists are
cytotoxic and able to restore the sensitivity of resistant
tumour cells to anti-tumour drugs such as doxorubicin and
vincristine and to increase the cytotoxicity of bleomycin but
that they do not increase the side-effects of anti-tumour
agents (Tsuro et al., 1982; Hait et al., 1985; Lazo et al., 1985;
Miller et al., 1988; Hait and Pierson, 1990). Some authors
pointed out that CaM may be a new target for antineoplastic
agents and CaM antagonists may be a group of new and
promising members of these agents (Hait and Lazo, 1986). It
seems that our data will fortify the theoretical basis for CaM
antagonists being used in the treatment of lung cancers.
In short, our findings suggest that CaM plays an
important role in the proliferation of lung cancer through
its promotion of uncontrolled DNA synthesis and CaM
antagonists may be promising new agents for the treatment
of lung cancers.
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